Jump to Content

Dr Agnes Vitry 

Position: Senior Lecturer
Division/Portfolio: Division of Health Sciences
School/Unit: School of Pharmacy and Medical Sciences
Campus: City East Campus
Office: P4-22
Telephone: +61 8 830 22392
Fax: +61 8 830 22389
Email: Agnes_dot_Vitry_at_unisa_dot_edu_dot_au
URL for Business Card: http://people.unisa.edu.au/Agnes.Vitry

I am a Senior Lecturer at the School of Pharmacy and Health Sciences.

My research focuses on three main areas:

- medicines policies in Australia and the Western Pacific Region: regulatory approval, funding, pricing, managed entry agreements, affordability, usage, and pharmaceutical promotion;

- quality use of medicines in people with comorbidities (elderly people, people living with cancer, residents of nursing homes).

- systematic reviews of trial and observational evidence on health outcomes of medicines.

In the recent years, I have collaborated with numerous organisations including the Australian Government’s Department of Health (Pharmaceutical Benefits Scheme (PBS) Post-Market Reviews), the Australian Commission on Safety and Quality in Health Care, the World Health Organization Western Pacific Region (WPRO) Office, and Health Action International.

I am strongly involved in the activities of consumer organisations in particular Cancer Voices SA with the development of a ‘patients as teachers’ academic program and several collaborative research projects.

I teach the following courses

PHAR 3021Quality Use of Medicines
HLTH 1025Health and Society

Professional associations

Member of the International Society for Pharmacoepidemiology (ISPE). ISPE is an international organization dedicated to advancing the health of the public by providing a forum for the open exchange of scientific information and for the development of policy; education; and advocacy for the field of pharmacoepidemiology, including pharmacovigilance, drug utilization research, and therapeutic risk management.

Member of Health Technology Assessment International (HTAi). The mission of HTAi is to support and promote the development, communication, understanding and use of health technology assessment (HTA) around the world, as a scientifically based and multidisciplinary means of informing decision making regarding the introduction of effective innovations and the efficient use of resources in health care.


1995 Masters in Economy and Management of Health Systems University Paris I (Pantheon-Sorbonne), France

1984 Diploma in Biological Statistics, Centre d'Enseignement de la Statistique Appliquée à la Médecine et à la Biologie Médicale, University Paris VI, Paris, France.

1984 Doctor of Philosophy (Pharmaceutical Sciences), University Paris XI, Faculty of Châtenay-Malabry, Paris, France

1981 Masters in Environmental Toxicology (Pharmaceutical Sciences) University Paris XI, Faculty of Châtenay-Malabry, Paris, France

1980 Bachelor of Pharmacy University Paris XI, Faculty of Châtenay-Malabry, Paris, France

Research interests

  • Quality use of medicines
  • Pharmaco-epidemiology
  • Medicines policies, pharmaceutical regulations, transparency of medicine agencies
  • Quality of medicines information for health professionals and consumers, clinical guidelines
  • Drug promotion, quality use of medicines, conflicts of interests
  • Assessment of new medicines

Research publications

My profile and publications on ORCiD

My profile and publications on Scopus

Vitry AI, Thai LP and Lu CY. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. Internal Medicine Journal (in press).

Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf 2010 Jul 7. [Epub ahead of print]

Lu CY, Barratt J, Vitry A, Roughead E. Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. J Clin Epi 2010 [Epub ahead of print]

Caughey GE, Roughead EE, Shakib S, McDermott RA, Vitry AI, Gilbert AL. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing 2010; 39 (4): 488-94.

Othman N, Vitry AI, Roughead EE. Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. BMC Public Health 2010 May 29;10: 294.

Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel versus clopidogrel for Cytochrome P450 2C19 genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010 May 21. [Epub ahead of print]

Vitry A. Reporting of studies on new medicines in major medical journals: a case study in breast cancer. Clinical Pharmacology and Therapeutics 2010; 87: 398–400.

Othman N, Vitry A and Roughead E. Medicines information in medical journal advertising in Australia, Malaysia and the United States. A comparative cross-sectional study. Southern Med Journal 2010; 3: 11-18.

Zhang Y, Vitry AI, Roughead EE, Ryan P and Gilbert A. Co-morbidity and the utilisation of health care for Australian veterans with diabetes. Diabetic medicine 2010; 27: 65–71.

Zhang Y, Chow V, Vitry A, Ryan P, Roughead E, Caughey G, Ramsay E, Gilbert A, Esterman A and Luszcz M. Antidepressant use and depressive symptoms among the older people from the Australian Longitudinal Study of Ageing. International Psychogeriatrics. 2010; 22 (3): 437-44.

Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S and Gilbert AL. Comorbidity in the elderly with diabetes; identification of areas of potential treatment conflicts. Diabetes Research and Clinical Practice 2010; 87 (3) :385-93.

Roughead,,E.E., Vitry, A.I., Preiss, K., Barratt, J.D., Gilbert, A.L., Ryan, P. Assessing overall duration of recommended cardiovascular medicines in veterans with established cardiovascular disease. Eur J Cardiov Prev 2010 Feb;17 (1): 71-6.

Othman N, Vitry AI, Roughead EE. Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. BMC Public Health 2010 May 29;10: 294.

Vitry A. Does direct-to-consumer prescription drug advertising do more harm than good? Ann Intern Medicine 2009; 151 (11): 823-824.

Goh LY, Vitry AI, Semple SJ, Esterman A and Luszcz M. Self-medication with over-the-counter drugs and complementary medications in South Australia's elderly population. BMC Complementary and Alternative Medicine 2009; 9 (1): 42.

Vitry A. Written medicine information in Australia, answer to the letter to the editor. Pharm World Sci 2009; 31:605–606.

Caughey E.G., Ramsay E. N., Vitry A. I., Gilbert A.L., Luszcz M.A., Ryan P.J., Roughead E.E. Comorbid chronic diseases, discordant impact on mortality in the elderly; a 14 year longitudinal population study. J Epidemiol Commun Health (online doi:10.1136/jech.2009.088260). Impact Factor: 3.186

Thomas R., Vitry, A. Consumers’ perception of generic medicines in community pharmacy in Malaysia. Southern Med Journal 2009; 2:20-23.

Othman N., Vitry A.I., Roughead E.E. Quality of pharmaceutical advertisements in medical journals: a systematic review. Plos one 2009; 4 (7): e6350.

Vitry, A., Hoile, A.P., Gilbert, A.L., Esterman, A. and Luszcz M. The risk of falls and fractures associated with persistent use of psychotropic medications in elderly people. Arch Gerontol Geriatr, 2009; 50 (3): e1-4.

Vitry A, Gilbert A, Mott K, Rao D, March G. Provision of medicines information in Australian community pharmacies. Pharm World and Sci. 2009; 31(2):154 -7.

Vitry A, Bertele V, Garattini S. Drug regulation and the need for greater transparency. RAJ Pharma. 2009 March; 20:143-6.

Vitry, A., Wong, S., Roughead, E. E., Ramsay, E., Barratt, J. Validity of medication-based comorbidity indices in the Australian elderly population. Australian and New Zealand Journal of Public Health 2009; 33: 126-130.

Vitry A and Lai Yi Hua. Advertising of antihypertensive medicines and prescription sales in Australia. Int Med J 2009; 39 (11): 728-732.

Vitry A, Phillips S and Semple S. Quality and availability of consumer Information on heart failure in Australia BMC Health Services Research 2008, 8:255.

Vitry A. Time for transparency at the TGA. Aust Prescr 2008;31:114-5.

Vitry AI and Zhang Y. Quality of Australian clinical guidelines and relevance to the care of elderly people with multiple morbidities. Med J Aust 2008; 189 (7): 360-365.

Caughey GE, Vitry AI, Roughead EE and Gilbert AL. Prevalence of multimorbidity of chronic diseases in Australia. BMC Public Health 2008;8:221.

Roughead EE, Gilbert AL and Vitry AI. The Australian funding debate on Quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 2008; 88 (2): 250-257.

Vitry A, Lexchin J, Sasich L, Dupin-Spriet T, Reed T, Bertele V, Garattini S, Toop L and Hurley E. Provision of information on regulatory authorities’ websites. Intern Med J 2008; 38 (7): 559-567.

Vitry A, Lexchin J and Mansfield PR. Is Australia’s national medicines policy failing? The case of Cox-2 inhibitors. In Power, Politics and Pharmaceuticals, eds Kathy Glavanis Grantham and Orla O'Donovan. Cork University Press, 2008.

Vitry A, Lexchin J and Mansfield PR. Is Australia’s national medicines policy failing? The case of Cox-2 inhibitors. IJHS 2007; 37(4): 735-744.

Vitry, A. Comparative assessment of four drug interaction compendia. BJCP 2007; 63(6); 709-714.

Vitry A, Mintzes B and Lexchin A. Direct-to-consumer advertising policy in Australia: realism in whose interests? Intern Med J. 2007 Sep;37(9):665-6.

Harvey K, Vitry A, Roughead E, Aroni R, Ballenden N and Fagotter R. Pharmaceutical advertisements in prescribing software: an analysis. MJA 2005; 183: 75-79.

Roughead E, Semple S and Vitry A. Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy Practice 2005; 13: 1-18.

Mansfield P and Vitry A. Rofecoxib withdrawal. Aust Prescr 2005 28: 30.

Mansfield P and Vitry A. Withdraw all COX-2-selective drugs. MJA 2005; 183: 75-79.

Vitry A. Is Australia free from direct-to-consumer advertising? Australian Prescriber 2004; 27: 4-6.

Mansfield P, Lexchin J, Vitry A, Doecke C and Svensson S. Drug advertising in medical journals. Lancet 2003; 361: 879.

Vitry A. And next: a flask of wine for Daddy? Australian Prescriber 2003; 26: 102.

Vitry A and Hurley E. The road to consensus: considerations for the safe use and prescribing of COX-2 specific inhibitors. MJA 2002; 177: 572.

Vitry A, Corbillon E and Pouillie A. Usefulness of virtual colonoscopy in colorectal cancer detection. Acta Endoscopica 2002; 32 (4) 665-681.

Gabb G and Vitry A. Electronic prescribing. Aust Prescriber 1999; 22: 28.

Gabb G and Vitry A. Choosing between old and new drugs. Aust Prescriber 1999; 22: 4.

Vitry A and Mansfield P. Drug advertisements in medical journals. Lancet 1997; 350: 1477-8.

Bhutta T and Vitry A. Treating dysentery with metronidazole in Pakistan. BMJ 1997; 314:146-7.

Vitry A and Mansfield P. Promotion of Coversyl by Servier. Lancet 1996; 347: 1411.

Vitry A. Pharmaceutical promotion: drug advertising affects your prescribing. Aust Prescriber 1996; 19: 103.

Chirac P, Pikon A, Poinsignon Y and Vitry A. Drug marketing in French-speaking African countries. Soc Sci Med 1993; 16: 1541-3.

Vitry A and Fardeau JM. France: stricter rules for drug exports. Lancet 1992; 340: 167.

Belhaouari M, Marty MH, Sorbette F and Vitry A. Réactions causées par le bleu patenté au cours de la lymphographie [Reactions caused by patent blue observed in lymphography]. Thérapie 1989; 44: 377-8.

Expertise for Media Contact

I am able to provide media comment in the following areas of expertise:

Discipline: Pharmacy

  • Quality Use of Medicines
  • Medicines policy
  • Drug promotion
  • Drug information
  • Consumer information

Community Service

Organisation Name:   Healthy Skepticism
Type of Organisation:   Community organisation
Level of involvement:   Member, Researcher
Year from:   1990
Year to:   2008

Organisation Name:   Health Action International
Type of Organisation:   Community organisation
Organisation URL:   http://www.haiweb.org/
Level of involvement:   Active Member
Year from:   1990
Year to:   2008
Comments:   HAI works towards a world in which all people, especially the poor and marginalised, are able to exercise their human right to health. HAI’s contribution is through advocating for increased access to essential medicines and improved rational use of medicines (RUM). This is achieved through research excellence and the engagement of civil society in advocacy in the medicines policy debate.

Organisation Name:   NHMRC
Type of Organisation:   Government Board or committee
Level of involvement:    Consultant / advisor
Year from:   2002
Year to:   2005

Organisation Name:   Cancer Voices SA
Type of Organisation:   Community organisation
Organisation URL:   http://www.cancervoicessa.org/
Level of involvement:   Active Member, Advisory/Researcher capacity
Year from:   2009

Organisation Name:   Cancer Australia
Section:   Cancer Australia Consumer Network
Type of Organisation:   Professional organisation
Level of involvement:    Consultant / advisor
Year from:   2010

Research Degree Supervisor

I conduct research in a wide range of areas related to the quality use of medicines: pharmacoepidemiology, medicines policies, quality of medicine information, influence of drug promotion. I have supervised one PhD student and many Honours Pharmacy students.

Change | Staff home page help